Skip Navigation

Agriculture & Environment: Standards of care

News

  • Print
  • Comment
  • | Share

South Africa backs down on nevirapine

James Njoroge

14 October 2002 | EN

[NAIROBI] The South African government announced last week that it would investigate ways of providing the anti-AIDS drug nevirapine to all HIV-positive pregnant women and their newborn babies throughout the country.

The announcement follows a ruling by the country's supreme court in July requiring the government to provide the drug — which is said to cut mother-to-child transmission of the disease by up to half — in all public hospitals.

The government had earlier refused to provide nevirapine in state-run health centres, citing cost and safety concerns over the drug, even though around 100,000 HIV-positive babies are born in South Africa every year, and many do not live beyond their fifth birthday.

Making the announcement, the Deputy President, Jacob Zuma, said four of the country's nine provinces — Gauteng, Western Cape, Northwest and KwaZulu Natal — had already extended the provision of the anti-retroviral beyond initial pilot sites.

"Following the ruling of the constitutional court on nevirapine, all the provinces have been provided with guidelines for the implementation of the prevention of mother-to-child transmission programme," said Nzuma, who also heads the South African National Aids Council.

© SciDev.Net 2002

Add your comment

This is your network: share your views on any of our articles by adding your comments.

You need to be signed in to post a comment or to email a consenting comment author. Please sign in or sign up.

All comments are subject to approval and we reserve the right to edit comments containing inappropriate/unsuitable language. SciDev.Net holds copyright for all material posted on the website. Please see terms of use for further details.

All SciDev.Net material is free to reproduce providing that the source and author are appropriately credited. For further details see Creative Commons.

Back to News
To the top